Rituximab (MabThera^®) – a new biological medicine in rheumatoid arthritis therapy

Czech version

Authors: P. Němec
Authors‘ workplace: Revmatologická ambulance II. interní kliniky Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
Published in: Vnitř Lék 2007; 53(11): 1199-1210
Category: Reviews

Overview

Rheumatoid arthritis (RA) is a serious, chronic, inflammatory disorder that damages the joints. The chronic destructive process causes pain to patients with RA and leads to the development of permanent disability. At present, great emphasis is placed on timely and effective therapy for RA, which is able to halt or slow the development of the disorder. At present we do not have any means of curing RA, the main objective for treatment is to induce remission of the disorder and prevent structural damage to the joints and the development of permanent disability. The relatively frequent failure of disease modifying medications (DMARDs) lead to efforts to find new resources for the treatment of RA. So called biological medicines were recently introduced into therapeutic use. These were mainly TNFα blockers. Experience has shown that approximately a third of patients with RA do not respond even to treatment with such medicines. Rituximab (MabThera^®), a monoclonal antibody against CD20 positive B-lymphocytes, is a new biological medicine approved for RA therapy. It represents a new hope for patients with active RA, for whom earlier therapy with TNFα blockers has failed.

Key words:
rheumatoid arthritis – rituximab – therapies

Sources

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911.

2. Lawrence RC, Helmick GG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculosceletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799.

3. Weinblatt ME. Rheumatoid arthritis: treat now, not later. Ann Intern Med 1996; 124: 773-774.

4. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the “side effects” or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004; 22(Suppl 35): S2-S11.

5. Visser H, le Cessie S, Vos K et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-365.

6. Brennan P, Harrison B, Barrett E et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 1996; 313: 471-476.

7. Möttönen T, Paimela L, Leirisalo-Repo M et al. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with “sawtooth” strategy. Ann Rheum Dis 1998; 57: 533-539.

8. Goronzy JJ, Matteson EL, Fulbright JW et al. Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2004; 50: 43-54.

9. Vencovský J, Macháček S, Šedová L et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 427-430.

10. Combe B, Dougados M, Goupille P et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44: 1736-1743.

11. Dixey J, Solymossy C, Young A. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004; 69: 48-54.

12. Combe B, Landwe R, Lukas C et al. EULAR recommendations for management of early arthritis. Ann Rheum Dis 2006; 5 [Epub, v tisku].

13. American College of Rheumatology (ACR). American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 2002; 46: 328-346.

14. Combe B, Landewé R, Lukas C et al. EULAR recommendations for the management of early arthritis. Ann Rheum Dis 2007; 66: 34-45.

15. Pavelka K, Bečvář R, Olejárová M et al. Standardní postupy v revmatologii. Revmatoidní artritida. Čes Revmatol 1999; 7(Suppl. 1): 4-8.

16. Vencovský J, Tegzová D, Pavelka K. Doplněk standardních postupů u revmatoidní artritidy. Čes Revmatol 2002; 10: 31-40.

17. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-2550.

18. Drosos AA, Tsifetaki N, Tsiakou EK et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 1997; 15: 263-267.

19. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593.

20. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naive patients with early, aggressive rheumatoid arthritis. Arthritis Rheum 2006; 54: 26-37.

21. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.

22. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-259.

23. Klareskog L, van der Heijde O, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.

24. Lipsky PE, van der Heijde DM, St Clair EW et al. and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infiximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-1602.

25. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.

26. Moreland L Unmet needs in rheumatoid arthritis. Arthritis Res Ther 2005; 7 (Suppl. 3): S2-S8.

27. Imperato AK, Bingham CO 3rd, Abramson SB Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22(Suppl 35): S108-S114.

28. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63: 1062-1068.

29. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 1114-1123.

30. Kremer JM, Weinblatt ME, Bankhurst AD et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA41g. N Engl J Med 2003; 349: 1907-1915.

31. Reff ME, Carner K, Chambers KS et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to C020. Blood 1994; 83: 435-445.

32. Maloney DG, Smith B, Appelbaum FR. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines. Blood 1996; 88 (Suppl. 1): 637a.

33. Breedveld F, Agarwal S, Yin M et al. Relationship between clinical response, rituximab pharmacokinetics, and peripheral B cell levels in rheumatoid arthritis. Presented at ACR 2005 (Abstract 279).

34. Ng CM, Bruno R, Combs D et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a Phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.

35. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581.

36. Emery P, Sheeran T, Lehane PB et al. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Arthritis Rheum 2004; 50 (Suppl. 9): S659.

37. Emery P, Fillpowicz-Sosnowska A, Szczepanski L et al. Primary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER trial). Ann Rheum Dis 2005: 64: 58.

38. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIb double-blind, placebo-controlled, dose-ranging trial (DANCER). Arthritis Rheum 2006; 54: 1390-1400.

39. Cohen SB, Emery P, Greenwald M et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2793-2806.

40. Protheroe A, Edwards JC, Simmons A et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) 1999; 38: 1150-1152.

41. Stewart M, Malkovska V, Krishnan J et al. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 2001; 60: 892-893.

42. Shaw T, Quan J, Totoritis MC B-cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003; 62 (Suppl. 2): ii55-ii59.

43. Czuczman MS Combination chemotherapy and rituximab. Anticancer Drugs 2001; 12 (Suppl. 2): S15-S19.

44. Sheeran T, Emery P, Lehane PB et al. Duration of response to a single treatment course of rituximab (RTX) in active rheumatoid arthritis (RA): efficacy and safety data from a 2-year follow-up of a randomised trial. Rheumatology (Oxford) 2005; 44: i2.

45. Keystone EC, Burmester GR, Furie R et al. Improved healthrelated quality of life with rituximab pius methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TN F therapies. ACR 2005 (Abstract 287).

46. Kremer JM, Tony H, Tak PP et al. Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006; 65 (Suppl. 2): 326.

47. Cohen S, Emery P, Greenwald M et al. Prolonged efficacy of a single course of rituximab in rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors: 1-year follow-up of a controlled trial (REFLEX study). Ann Rheum Dis 2006; 65 (Suppl. 2): 183.

48. Keystone EC, Fleischmann R, Emery P et al. Long term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 2006; 65 (Suppl. 2): 323-324.

49. Keystone E, Emery P, Peterfy CD et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). Ann Rheum Dis 2006; 65 (Suppl. 2): 58.

50. van Vollenhoven RF, Emery P, Bingham C et al. Safety of rituximab in rheumatoid arthritis: results of a pooled analysis. Ann Rheum Dis 2006: 65 (Suppl. 2): 503.

51. van Vollenhoven RF, Emery P, Fleischmann RM et al. Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis (RA): results from the Dose-ranging Assessment iNternational Clinical Evaluation of Rituximab in RA (DANCER) study. Ann Rheum Dis 2005: 64: 432.

52. Fleischmann RM, Racewicz AJ, Schechtman J et al. Rituximab efficacy in rheumatoid arthritis is independent of coadministration of glucocorticoids: results from the Dose-ranging Assessment iNternational Clinical Evaluation of Rituximab in rheumatoid arthritis (DANCER) Study. Arthritis Rheum 2005; 52 (Abstract 263).

53. Doran MF, Crowson CS, Pond GR et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-2300.

54. Breedveld FC, Genovese M, Emery P et al. Safety of TNF inhibitors in rheumatoid arthritis patients previously treated with rituximab. Ann Rheum Dis 2006: 65 (Suppl. 2): 178-179.

55. Dixon W, Watson K, Hyrich K et al. The incidence of serious infections is not increased in patients with rheumatoid arthritis treated with anti-TNF drugs compared to those treated with traditional DMARDs: results from a national prospective study. ACR 2005 (Abstract 1990).